Produktname:1-Ethyl-4-(4-nitrophenyl)piperazine

IUPAC Name:1-ethyl-4-(4-nitrophenyl)piperazine

CAS:115619-00-6
Molekulare Formel:C12H17N3O2
Reinheit:95%
Katalognummer:CM120162
Molekulargewicht:235.29

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM120162-5g in stock ǫŞ
CM120162-10g in stock Ÿƴƴ
CM120162-25g in stock ƚǫŞ
CM120162-100g 1-2 Weeks ŪȖǫ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:115619-00-6
Molekulare Formel:C12H17N3O2
Schmelzpunkt:-
SMILES-Code:O=[N+](C1=CC=C(N2CCN(CC)CC2)C=C1)[O-]
Dichte:
Katalognummer:CM120162
Molekulargewicht:235.29
Siedepunkt:
Mdl-Nr.:MFCD00614372
Lagerung:Store at room temperature.

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

Column Infos

Infigratinib
Sept. 06, 2023, positive feedback from the U.S. FDA and the EU EMA on key elements of the trial design for PROPEL3, its pivotal Phase 3 study of infigratinib in children with achondroplasia.
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the United States and European Union, including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating mutation in FGFR3.
Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source. It is incredibly exciting that infigratinib has the potential to become the first effective oral treatment option to improve growth, enhance functionality and decrease complications.

Related Products